Arcellx sinks following results from Kelonia CAR-T therapy for multiple myeloma

Arcellx (ACLX) closed down ~17% Monday after privately held Kelonia Therapeutics released early-stage results from a small ...
Cosmetics Business

Lubrizol Unveils New Data on Telophi Biotech Ingredient and Skin Regeneration

Lubrizol announces new scientific findings supporting the efficacy of its Telophi biotech ingredient Recent ex vivo and in vitro studies confirm that it helps protect telocytes and stem cells from ...

Kelonia Therapeutics Announces Late-Breaking Oral Presentation of First-in-Human Data from in vivo BCMA CAR-T Therapy at the American Society of Hematology (ASH) 2025 Annual ...

Kelonia Therapeutics, Inc., a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced that its first results from the ongoing inMMyCAR study, a Phase 1 clinical trial ...
Cure Today

In Vivo CAR T-Cell Approach May Lower Kidney Cancer Treatment Cost

Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...